All News
Filter News
Found 4,294 articles
-
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
4/8/2024
Elevation Oncology, Inc. (Nasdaq: ELEV) today announced new preclinical data demonstrating proof-of-concept for its differentiated HER3-ADC program.
-
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
4/8/2024
CytomX Therapeutics, Inc. today announced the first patient has been dosed in a Phase 1 dose escalation study ( NCT06265688 ) of CX-2051 in patients with advanced solid tumors.
-
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
4/8/2024
Zymeworks Inc. announced five presentations including new data from its preclinical development-stage programs at the 2024 American Association for Cancer Research Annual Meeting being held in San Diego, California April 5-10, 2024.
-
Defence Therapeutics Announces Warrant Terms Amendment
4/8/2024
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in the field of immune-oncology, announces an amendment to the terms of 1,497,780 Class A Common share purchase warrants (the "Warrants") originally issued as part of a private placement closed on November 16, 2022.
-
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024Poster presentation highlights strong safety and pharmacokinetic profiles for LNCB74
4/8/2024
NextCure, Inc. (Nasdaq: NXTC) today announced the presentation of new preclinical data on LNCB74, a B7-H4-targeting antibody drug conjugate (ADC) developed in partnership with LigaChem Biosciences (LCB), formerly LegoChem Biosciences, (KOSDAQ: 141080), at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.
-
Adcentrx Therapeutics Appoints Meng Jiang as Chief Financial Officer
4/8/2024
Adcentrx Therapeutics ("Adcentrx"), a biotechnology company revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, announced today the appointment of Meng Jiang as Chief Financial Officer (CFO).
-
Mythic Therapeutics Presents Preclinical Data on MYTX-011, an Investigational cMET-Targeting Antibody-Drug Conjugate (ADC), at the American Association for Cancer Research (AACR) Annual Meeting
4/8/2024
Mythic Therapeutics, a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, presented preclinical data from MYTX-011, its investigational cMET-targeting ADC, at the American Association for Cancer Research (AACR) Annual Meeting.
-
Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024
4/8/2024
Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today presented positive preliminary Phase 1 data for VIP236 and updates on pipeline progress at the American Association for Cancer Research (AACR) Annual Meeting 2024.
-
Tubulis Presents Preclinical Data for Solid Tumor Targeting ADC Candidates TUB-030 and TUB-040 Demonstrating Superior Efficacy Profile and a Wide Therapeutic Window at the AACR Annual Meeting 2024
4/8/2024
Tubulis today presented comprehensive preclinical data on its two lead antibody-drug conjugate (ADC) candidates TUB-030 and TUB-040 at this year’s Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.
-
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
4/7/2024
BioNTech SE announced three-year follow-up data from a Phase 1 trial with the mRNA-based individualized neoantigen-specific immunotherapy candidate autogene cevumeran in patients with resected pancreatic ductal adenocarcinoma.
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors
4/6/2024
AstraZeneca and Daiichi Sankyo's ENHERTU® has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.
-
Antengene Presents Four Preclinical Posters at AACR 2024
4/6/2024
Antengene Corporation Limited announced the presentation of four preclinical posters at the 2024 American Association for Cancer Research Annual Meeting, taking place from April 5th to April 10th at the San Diego Convention Center in San Diego, California, the United States.
-
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
4/6/2024
Legend Biotech Corporation announced the U.S. Food and Drug Administration has approved CARVYKTI® for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor, and an immunomodulatory agent, and are refractory to lenalidomide.
-
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
4/6/2024
Daiichi Sankyo and AstraZeneca’s ENHERTU® has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.
-
Recent warnings about Chinese biopharma partners from members of Congress and U.S. intelligence officials have reached a fever pitch in Washington.
-
Araris Biotech AG Presents Data on Novel Antibody-Drug Conjugates at American Association for Cancer Research (AACR) Annual Meeting 2024
4/5/2024
Araris Biotech AG announced the company will deliver two poster presentations, including one late-breaking poster, at this year’s American Association for Cancer Research Annual Meeting being held April 5-10, 2024 at the San Diego Convention Center in San Diego, California.
-
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
4/5/2024
HUTCHMED Limited announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.
-
Shasqi to Present Data on Novel Tumor-Targeted Drug Activation Technology at 2024 American Association for Cancer Research (AACR) Annual Meeting
4/5/2024
Shasqi, Inc. today announced it will present five posters on the company's novel tumor-targeted drug activation approach at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, April 5-10, 2024.
-
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
4/5/2024
Immunome, Inc. today announced that it will present preclinical data for IM-3050, the company’s lead lutetium-177 radioligand therapy (RLT) targeting fibroblast activation protein (FAP).
-
Nucleai Unveils Breakthrough AI Spatial Biomarker Advancements at AACR 2024 with the Potential to Transform Cancer Diagnostics and Treatments
4/5/2024
Nucleai, a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, will showcase its developments in cancer research and diagnostics at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California from April 5-10, 2024.